Autres langues Vertex Pharmaceuticals Incorporated

Actions

VRTX

US92532F1003

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 28/09/2026			Varia. 5j.	Varia. 1 janv.
527,67 ^USD	+0,28 %		+3,32 %	+16,39 %

28/09	Vertex Pharmaceuticals Incorporated : UBS reste à l'achat	ZM
23/09	Vertex Pharmaceuticals Incorporated : Jefferies & Co. toujours à l'achat	ZM

Autres langues

22/09	Health Care Up as Viking Surges - Health Care Roundup
22/09	Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2b AMPLIFIED Study Of Inaxaplin And Completes Enrollment In The Phase 2/3 AMPLITUDE Trial
22/09	Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial
22/09	Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
15/09	Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
01/09	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027
01/09	Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027
01/09	Vertex Pharmaceuticals Incorporated completed the acquisition of Crinetics Pharmaceuticals, Inc. from a group of shareholders.
01/09	Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes
01/09	Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition
01/09	Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
26/08	Vertex to Participate in Upcoming September Investor Conferences
12/08	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says
10/08	Vertex Shares Rise as Rival Sionna's Cystic-Fibrosis Trial Fails to Meet Endpoint
10/08	Sionna scraps genetic disorder drug program after trial setback; shares tank
05/08	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)
04/08	Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced on May 19, 2025.
04/08	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says
04/08	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says
03/08	Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs
03/08	Vertex: Q2 Earnings Snapshot
03/08	Vertex Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance
03/08	(VRTX) Vertex Pharmaceuticals Now Expects 2026 Revenue Range $13.1B-$13.2B, vs. FactSet Est of $13.06B
03/08	Vertex raises annual revenue forecast on cystic fibrosis drugs strength
03/08	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Reports Q2 Revenue $3.33B, vs. FactSet Est of $3.23B